Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER vs AKNE-MYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Topical treatment of acne vulgaris
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Topical application of 2% solution twice daily to affected areas.
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Not systemically absorbed to a clinically significant degree after topical application. If absorbed, erythromycin is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4.
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Bound primarily to albumin (10-20%)
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
0.2-0.3 L/kg, indicating limited extravascular distribution (primarily extracellular fluid)
Intravenous: 100%.
Topical: 2-5% (minimal systemic absorption); oral: 75-85%
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
No dosage adjustment required for topical use; systemic absorption negligible.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
No dosage adjustment required for topical use; systemic absorption negligible.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Safety and efficacy not established in children under 12 years; for age ≥12 years, same as adult dosing.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
No specific adjustments; use with caution due to potential increased skin sensitivity.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
None
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
For external use only; avoid contact with eyes, mouth, and mucous membranes. May cause skin irritation, burning, stinging, or dryness. Reported cases of pseudomembranous colitis with topical use (rare). Use with caution in patients with hepatic impairment if significant systemic absorption occurs. Cross-resistance with other macrolides may develop. Use during pregnancy only if clearly needed (category B).
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
Hypersensitivity to erythromycin or any component of the formulation. Concurrent use with pimozide or ergot alkaloids (potential for QT prolongation and ergotism, though systemic absorption low).
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
No specific food interactions. Take with or without food. Avoid excessive intake of spicy or greasy foods, which may exacerbate acne.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with topical use, but risk cannot be completely excluded. First trimester: low risk, but use only if clearly needed. Second and third trimesters: generally considered safe with minimal systemic exposure.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
Erythromycin is excreted in human milk in small amounts. Topical Akne-Mycin results in negligible systemic absorption, making significant infant exposure unlikely. M/P ratio not reported for topical use; oral erythromycin M/P ratio is approximately 0.5. Caution is advised, but use is generally compatible with breastfeeding.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
No dose adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not clinically relevant for topical Akne-Mycin due to minimal systemic absorption. Apply as directed regardless of pregnancy trimester.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
Akne-Mycin (erythromycin topical) is effective for mild to moderate acne vulgaris. It can be combined with benzoyl peroxide to reduce antibiotic resistance. Avoid use with other topical erythromycin products to prevent overuse. Monitor for local skin reactions like erythema, scaling, or itching.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
Apply a thin layer to affected areas once or twice daily as directed.,Wash skin gently with mild soap and pat dry before application.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use more often than prescribed; overuse can increase irritation.,Inform your doctor if you develop severe redness, peeling, or discomfort.,Use sunscreen daily as this medication may increase sun sensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER vs AKNE-MYCIN, answered by our medical review team.
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. AKNE-MYCIN is a Topical Antibiotic that works by Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER and AKNE-MYCIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. The standard adult dose of AKNE-MYCIN is: Topical application of 2% solution twice daily to affected areas.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER and AKNE-MYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. AKNE-MYCIN is classified as Category C. Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.